Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ebola Virus Infection”

129 trials

Showing 20 of 129 results

Early research (Phase 1)Study completedNCT02376426
What this trial is testing

Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Who this might be right for
Healthy
Crucell Holland BV 72
Not applicableStudy completedNCT05313139
What this trial is testing

Surveillance of Vaccine-induced Immunity Against Ebola in Previously Vaccinated Health Care Workers

Who this might be right for
Immune Response
Institute of Tropical Medicine, Belgium 133
Early research (Phase 1)Study completedNCT05724472
What this trial is testing

Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health

Who this might be right for
Ebola Sudan Virus Disease
International AIDS Vaccine Initiative 36
Not applicableStudy completedNCT05494801
What this trial is testing

Natural History, Disease Progression, and Long-Term Neurologic Sequelae of Ebola Virus Disease (EVD) Survivors in PREVAIL III

Who this might be right for
Ebola Virus Disease
National Institute of Allergy and Infectious Diseases (NIAID) 203
Early research (Phase 1)Study completedNCT02370589
What this trial is testing

Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects

Who this might be right for
Ebola
Novavax 230
Large-scale testing (Phase 3)Study completedNCT04556526
What this trial is testing

A 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women

Who this might be right for
Healthy
Janssen Vaccines & Prevention B.V. 4,031
Testing effectiveness (Phase 2)WithdrawnNCT02271347
What this trial is testing

An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease

Who this might be right for
Ebola Virus
Jazz Pharmaceuticals
Not applicableStudy completedNCT02911415
What this trial is testing

Open Study of the Duration of Immunity After Vaccination With GamEvac-Combi

Who this might be right for
Ebola Hemorrhagic Fever
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation 60
Testing effectiveness (Phase 2)Study completedNCT04028349
What this trial is testing

ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo)

Who this might be right for
Ebola Virus Disease
MRC/UVRI and LSHTM Uganda Research Unit 800
Not applicableAvailableNCT05067166
What this trial is testing

Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP

Who this might be right for
Ebola Virus Disease
Ridgeback Biotherapeutics, LP
Early research (Phase 1)Study completedNCT02891980
What this trial is testing

A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers

Who this might be right for
Ebola DiseaseMarburg Disease
National Institute of Allergy and Infectious Diseases (NIAID) 65
Testing effectiveness (Phase 2)Study completedNCT03031912
What this trial is testing

African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola

Who this might be right for
Ebola
Canadian Immunization Research Network 251
Not applicableStudy completedNCT02911428
What this trial is testing

Open Study of the Duration of Immunity After Vaccination With GamEvac

Who this might be right for
Hemorrhagic Fever, Ebola
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation 60
Post-approval studies (Phase 4)Study completedNCT03072030
What this trial is testing

International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi

Who this might be right for
Ebola Virus DiseasePrevention
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation 2,000
Not applicableStudy completedNCT02658331
What this trial is testing

Evaluation of the FilmArray BioThreat-E Test

Who this might be right for
Ebola Virus Disease
BioMérieux 156
Testing effectiveness (Phase 2)Study completedNCT02564523
What this trial is testing

Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults

Who this might be right for
Hemorrhagic Fever, Ebola
Janssen Vaccines & Prevention B.V. 1,075
Early research (Phase 1)Study completedNCT02495246
What this trial is testing

Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV

Who this might be right for
Ebola Virus Disease
University of Oxford 32
Testing effectiveness (Phase 2)Study completedNCT04186000
What this trial is testing

Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola

Who this might be right for
Ebola Virus Disease
Universiteit Antwerpen 699
Early research (Phase 1)Study completedNCT02267109
What this trial is testing

Phase 1 Trial of Ebola Vaccine in Mali

Who this might be right for
Ebola Virus DiseaseHemorrhagic Fever
University of Maryland, Baltimore 91
Early research (Phase 1)Study completedNCT02231866
What this trial is testing

Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults

Who this might be right for
Healthy Adult Immune Responses to Vaccine
National Institute of Allergy and Infectious Diseases (NIAID) 143
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation